Ubushinwa bushya budasanzwe bwo kuvura kanseri y'ibihaha

# Ubushinwa Ubuvuzi bushya bwa kanseri y'ibihaha itari mito mito Ubuvuzi bushya bwa kanseri y'ibihaha itari ntoya (NSCLC) burahora buhinduka mu Bushinwa. Iyi ngingo itanga incamake yiterambere rigezweho, yibanda kubuvuzi bugenewe, immunotherapie, nubundi buryo bushya bushoboka abarwayi. Tuzasesengura imiterere ya Ubushinwa bushya bushya bwo kuvura kanseri y'ibihaha, kwerekana ibitekerezo byingenzi kubarwayi n'abarezi babo.

Ubuvuzi bugenewe NSCLC mubushinwa

Ubuvuzi bugamije kwerekana iterambere ryingenzi muri Ubushinwa bushya bushya bwo kuvura kanseri y'ibihaha. Iyi miti yibanda cyane cyane ku ihindagurika ry’imiterere itera ingirabuzimafatizo za kanseri. Ubuvuzi butandukanye bugamije kwerekana akamaro gakomeye mu kwagura ubuzima no kuzamura imibereho y’abarwayi bafite ihinduka ry’imihindagurikire.

EGFR Inhibitor

Epidermal growth factor reseptor (EGFR) ihinduka ryinshi muri NSCLC, cyane cyane kubarwayi batigeze banywa itabi. Inzitizi nyinshi za EGFR tyrosine kinase inhibitor (TKIs), nka gefitinib, erlotinib, afatinib, osimertinib, nizindi, ziraboneka mubushinwa kandi byagaragaje akamaro gakomeye mukuvura NSCLC yahinduwe na EGFR. Iyi miti ikora ihagarika inzira ya EGFR yerekana inzira, ikumira ikibyimba. Guhitamo EGFR-TKI yihariye biterwa nibintu nkubwoko bwa mutation ya EGFR nubuzima bwumurwayi muri rusange. Ingaruka n'ingaruka ziratandukanye hagati yiyi miti.

ALK Inhibitor

Anaplastique lymphoma kinase (ALK) itondekanya nubundi buryo busanzwe bwa genetike muri NSCLC. ALK inhibitor, nka crizotinib, ceritinib, alectinib, na brigatinib, yibasira iyi ihinduka. Kimwe na EGFR TKIs, guhitamo ALK inhibitor ikwiye ireba ibintu nkibisanzwe ALK itondekanya hamwe nibiranga abarwayi.

Ubundi buryo bwo kuvura

Kurenga EGFR na ALK inhibitor, ubundi buvuzi bugamije buraboneka mubushinwa kubarwayi ba NSCLC bafite ihindagurika ryihariye. Harimo ubuvuzi bugamije guhinduka muri ROS1, RET, na BRAF, nibindi. Kuboneka no kugerwaho nubuvuzi birashobora gutandukana mukarere mubushinwa. Kugumya kumenyeshwa binyuze mubiganiro naba oncologiste nibyingenzi kugirango ugere kumahitamo meza.

Immunotherapy kuri NSCLC mu Bushinwa

Immunotherapy ikoresha imbaraga z'umubiri z'umubiri zo kurwanya kanseri. Ubu buryo bwerekana paradigm ihinduka muri Ubushinwa bushya bushya bwo kuvura kanseri y'ibihaha kandi yerekanye intsinzi idasanzwe mugutezimbere ubuzima bwo kubaho kubarwayi benshi.

Immune Igenzura

Immune igenzura (ICIs) nicyiciro cyimiti yubudahangarwa ibuza poroteyine zifasha selile kanseri kwirinda ubudahangarwa bw'umubiri. Intego ebyiri nyamukuru kuri ICI ni gahunda yurupfu-1 (PD-1) hamwe na programme y'urupfu-ligand 1 (PD-L1). Pembrolizumab, nivolumab, na sintilimab ni ingero za PD-1 / PD-L1 inhibitor zemewe mu Bushinwa kuri NSCLC. Ikoreshwa rya ICI akenshi riyobowe nurwego rwa PD-L1 rwerekana imiterere yibibyimba, nubwo imikorere yabyo irenze imiterere ya PD-L1 mubihe bimwe. Gukurikirana neza ingaruka zishobora guterwa ni ngombwa.

Ubundi buryo bwo kuvura udushya

Ubushakashatsi bukomeje bukomeje guteza imbere udushya mu kuvura NSCLC. Ubuvuzi bushya, harimo nubuvuzi bugamije kurwanya biomarkers igaragara, guhuza immunotherapie hamwe nubuvuzi bugamije, hamwe nubundi buryo bushya, burimo gukorwa iperereza kandi butangiye kugira ingaruka mubikorwa byubuvuzi. Umwanya uratera imbere byihuse, kandi kugisha inama buri gihe nabashinzwe ubuvuzi bwihariye nibyingenzi kugirango bakomeze kugezwaho amakuru agezweho. Kumakuru yukuri kandi agezweho, nyamuneka saba muganga wawe.

Guhitamo uburyo bwiza

Uburyo bwiza bwo kuvura NSCLC mu Bushinwa bwihariye kandi bushingiye ku bintu byinshi birimo icyiciro cya kanseri, ihinduka ry’imiterere ihindagurika, ubuzima bw’umurwayi muri rusange, ndetse n’ubuvuzi bwihariye. Ibiganiro na oncologue kabuhariwe muri kanseri yibihaha nibyingenzi muguhitamo ingamba zikwiye kandi nziza zo kuvura. Ikigo cy'ubushakashatsi cya Kanseri ya Shandong Baofa (https://www.baofahospital.com/) ni ikigo cyambere mubushinwa gitanga ubuvuzi bwa kanseri.

Ingaruka zo Kuvura Ingaruka nubuyobozi

Imiti myinshi ivura kanseri, harimo n'iya NSCLC, irashobora kugira ingaruka. Izi ngaruka mbi ziratandukanye bitewe nubuvuzi bwihariye numurwayi kugiti cye. Gufungura itumanaho hamwe nitsinda ryanyu ryita ku ngaruka zose ni ngombwa mu kubicunga neza. Serivisi zifasha hamwe ningamba zo gucunga ingaruka zirahari kugirango habeho ihumure nubuzima bwiza mugihe cyose bivurwa.

Umwanzuro

Imiterere ya Ubushinwa bushya bushya bwo kuvura kanseri y'ibihaha ni imbaraga kandi zitanga ikizere. Iterambere mubuvuzi bugamije, immunotherapy, nubundi buryo butanga ibyiringiro kubarwayi. Kumenya hakiri kare no kwisuzumisha byihuse nibyingenzi kugirango ubone uburyo bwiza bwo kuvura. Gukorana cyane nitsinda ryanyu ryita ku buzima ni ngombwa kugira ngo ukemure ibibazo bigoye byo kuvura NSCLC no gukoresha amahirwe menshi yo gutsinda. Wibuke kugisha inama umuganga wawe oncologue kugirango muganire kumajyambere agezweho hamwe na gahunda nziza yo kuvura kubibazo byanyu byihariye.